Prediabetes breakdown: new drug combo aims to reverse blood sugar and save hearts
NCT ID NCT07392151
First seen Feb 06, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study tests whether glucose-lowering medications (semaglutide and dapagliflozin) can reverse prediabetes and prevent early diabetes complications in people with heart disease. About 158 participants with prediabetes and coronary artery disease will receive either the drugs plus lifestyle advice or standard care for one year. The goal is to see if treatment can bring blood sugar back to normal and reduce damage to eyes, kidneys, and nerves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREDIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
Aarhus N, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.